Acadia Pharmaceuticals

Historical price data

Acadia Pharmaceuticals' mission is to advance care for underserved neurological and rare disease communities by developing and commercializing innovative treatments where few or no options exist. Its key achievements include the landmark approvals of NUPLAZID® for Parkinson's disease psychosis and DAYBUE® for Rett syndrome, establishing two commercial pillars. The company's strategy is to leverage its commercial infrastructure and CNS expertise to maximize these assets while advancing a pipeline targeting significant adjacent indications like Alzheimer's disease psychosis. Acadia operates as a fully integrated, publicly traded organization with a growing international footprint.

Targeted, mechanism-driven neuroscience focused on identifying and modulating novel CNS targets, particularly in serotonin and neuroinflammation pathways, to develop selective small molecule therapies for complex neurological and rare diseases.

Acadia enjoys first-mover monopoly status with NUPLAZID® in PDP and DAYBUE® in Rett syndrome. Its primary competition is from off-label atypical antipsychotics for ADP, where NUPLAZID®'s differentiated safety profile is a key advantage, and from earlier-stage pipeline candidates in Rett syndrome, which are years behind.